Amyotrophic lateral sclerosis progression: Iran-ALS clinical registry, a multicentre study

作者：Shamshiri Hosein; Fatehi Farzad; Davoudi Farnoush; Mir Elham; Pourmirza Behin; Abolfazli Roya; Etemadifar Masoud; Harirchian Mohammad Hossein; Gharagozli Koroush; Ayromlou Hormoz; Basiri Keivan; Zamani Babak; Rohani Mohammad; Sedighi Behnaz; Roudbari Ali; Kasmaei Hossein Delavar; Nikkhah Karim; Naeini Alireza Ranjbar; Nafissi Shahriar^*

来源：Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16(7-8): 506-511.

DOI：10.3109/21678421.2015.1074698

• Amyotrophic lateral sclerosis
• progression rate
• Manual Muscle Test scoring
• revised ALS Functional Rating Scale

This study was designed to evaluate ALS progression among different subgroups of Iranian patients.Three hundred and fifty-eight patients from centres around the country were registered and their progression rate was evaluated using several scores including Manual Muscle Test scoring (MMT) and the revised ALS Functional Rating Scale (ALSFRS-R). Progression rate was analysed separately in subgroups regarding gender, onset site, stage of disease and riluzole consumption. A significant difference in MMT deterioration rate (p=0.01) was noted between those who used riluzole and those who did not. No significant difference was observed in progression rates between male/female and bulbar-onset/limb-onset groups using riluzole. In conclusion, riluzole has a significant effect on muscle force deterioration rate but not functional scale. Progression rate was not influenced by site of onset or gender.

• 出版日期2015-11-27